Sahajanand Medical Technologies IPO is fully book build issue and total IPO size is ₹[.] crores. The entire share offering is an offer for sale of 27644231 shares.
The dates for the Sahajanand Medical Technologies IPO have not been announced yet. The allotment process is expected to be finalized by [.].
The Sahajanand Medical Technologies IPO is scheduled to list on BSE, NSE, with a listing date of [.]. The price band for the Sahajanand Medical Technologies IPO has not been announced yet.
Registrar for this IPO is Mufg Intime India Private Limited and lead managers for Sahajanand Medical Technologies IPO are Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, Hsbc Securities And Capital Markets (India) Private Limited, Nuvama Wealth Management Limited.
IPO Schedule
| IPO Open Date | - |
|---|---|
| IPO Close Date | - |
| IPO Allotment Date | - |
| Refund Initiation | - |
| Share credit in Demat | - |
| Listing Date | - |
Key Details
| Price Band | TBA |
|---|---|
| Lot Size | TBA |
| Face Value | ₹1 Per Equity Share |
| Total Issue Size | 27,644,231 Shares |
| Fresh Issue | - |
| OFS Issue | 27,644,231 Shares |
| Issue Type | Offer for Sale |
| Listing At | BSE, NSE |
Share Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB | 50% |
| Retail | 35% |
| NII/HNI | 15% |
About Sahajanand Medical Technologies Limited Company
SMT Company Overview: SMT is an R&D-driven medical device company specializing in technologically advanced devices for vascular and structural heart intervention. Founded in 2001, SMT has a global presence across 76 countries (as of March 31, 2025). As of fiscal year 2025, the company's revenue from operations stood at ₹1,024.88 crore. SMT holds a significant market share in India's drug-eluting stent (DES) market, holding nearly 25% in Fiscal 2025.
Product Portfolio and Innovation: SMT's portfolio includes coronary stents and balloons (Vascular Intervention), Trans-Catheter Aortic Valves (TAVI) and Occluders (Structural Heart). SMT also holds 102 patents granted globally and 71 pending applications. Flagship products like Supraflex Cruz, Cocoon, and Hydra are endorsed by key opinion leaders and accepted by major European GPOs. In fiscal year 2025, revenue from VI devices was 65.86%, while SH devices contributed 15.35% and other products contributed 18.79%.
Global Reach and Manufacturing: SMT strategically balances direct operations with distributor-led models. The company operates three manufacturing facilities: two in India and one in Thailand. Revenue is geographically diverse, with India contributing 31.28%, Europe 32.96%, and the Rest of World 35.76% of the total in fiscal year 2025. EBITDA for Fiscal 2025 was ₹128.02 crore, with an EBITDA margin of 12.49%.
Sahajanand Medical Technologies Limited Financial Details
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 1094.90 | 970.58 | 911.63 |
| Revenue | 1024.88 | 901.60 | 795.55 |
| Profit After Tax | 25.15 | -7.35 | 11.93 |
| Net Worth | 590.47 | 566.32 | 573.10 |
| Reserves and Surplus | 555.97 | 530.34 | 543.58 |
| Total Borrowing | 224.96 | 175.27 | 132.18 |
₹ In Crore
Key Performance Indicator
| Basic EPS (in ₹) | Return on Net Worth (RoNW) | Net Asset Value (NAV) | Debt-Equity Ratio | Return on Equity (ROE) | Return on Capital Employed (ROCE) |
|---|---|---|---|---|---|
| 2.09 | 3.73% | 55.86 | NA | 3.68% | 10.37% |
Offer Objectives
The document details Employee Stock Option Plans (ESOPs) and the objects of an upcoming offer, specifically an Offer for Sale (OFS). Two ESOP pools (Pool 2 and Pool 3) are described, including options outstanding, granted, vested, exercised, and forfeited across different fiscal years. Pool 2 had options outstanding from Fiscal 2023-2025 and up to the date of the DRHP (Draft Red Herring Prospectus) with exercise prices at ₹ 1.00. The ESOP scheme has undergone multiple amendments to align with SEBI SBEBSE Regulations. Pool 3 has no options outstanding as of the DRHP date.
The OFS involves the sale of 27,644,231 Equity Shares, constituting 27.26% of the pre-offer equity, by Selling Shareholders. The company will not receive any proceeds; these will go to the Selling Shareholders after deducting offer-related expenses and taxes. The total estimated offer expenses are approximately ₹[●] million. The expenses include BRLMs' fees, brokerage, registrar fees, listing fees, legal counsel fees, and advertising costs. These expenses will be shared proportionally among the Selling Shareholders.
Various commissions and fees are detailed for SCSBs, Syndicate members, RTAs, and CDPs based on the type of bidder (Retail Individual Bidders and Non-Institutional Bidders) and the procurement method. Since the Offer is an OFS, the company is not required to appoint a monitoring agency. No proceeds will be received by Promoters, Directors, Key Managerial Personnel, or related parties, aside from those obtained through the sale of Offered Shares by the Selling Shareholders.
Company Details
Address:
Sahajanand Estate, Wakharia Wadi, NR. Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat 395 004, India
Phone: 022 49564000
Email: [email protected]
Website: http://www.smtpl.com
IPO Registrar Details
MUFG Intime India Private Limited
Phone: +91 810 811 4949
Email: [email protected]
Website: http://in.mpms.mufg.com
Offer Prospectus & Documents
Lead Managers
- Motilal Oswal Investment Advisors Limited
- Avendus Capital Private Limited
- HSBC Securities and Capital Markets (India) Private Limited
- Nuvama Wealth Management Limited
